271 related articles for article (PubMed ID: 32891191)
1. Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial.
Absalon J; Segall N; Block SL; Center KJ; Scully IL; Giardina PC; Peterson J; Watson WJ; Gruber WC; Jansen KU; Peng Y; Munson S; Pavliakova D; Scott DA; Anderson AS
Lancet Infect Dis; 2021 Feb; 21(2):263-274. PubMed ID: 32891191
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.
Madhi SA; Cutland CL; Jose L; Koen A; Govender N; Wittke F; Olugbosi M; Meulen AS; Baker S; Dull PM; Narasimhan V; Slobod K
Lancet Infect Dis; 2016 Aug; 16(8):923-34. PubMed ID: 27139805
[TBL] [Abstract][Full Text] [Related]
3. Potential for Maternally Administered Vaccine for Infant Group B Streptococcus.
Madhi SA; Anderson AS; Absalon J; Radley D; Simon R; Jongihlati B; Strehlau R; van Niekerk AM; Izu A; Naidoo N; Kwatra G; Ramsamy Y; Said M; Jones S; Jose L; Fairlie L; Barnabas SL; Newton R; Munson S; Jefferies Z; Pavliakova D; Silmon de Monerri NC; Gomme E; Perez JL; Scott DA; Gruber WC; Jansen KU
N Engl J Med; 2023 Jul; 389(3):215-227. PubMed ID: 37467497
[TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active comparator-controlled, multicentre, US-based trial.
Platt H; Omole T; Cardona J; Fraser NJ; Mularski RA; Andrews C; Daboul N; Gallagher N; Sapre A; Li J; Polis A; Fernsler D; Tamms G; Xu W; Murphy R; Skinner J; Joyce J; Musey L
Lancet Infect Dis; 2023 Feb; 23(2):233-246. PubMed ID: 36116461
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.
Groome MJ; Fairlie L; Morrison J; Fix A; Koen A; Masenya M; Jose L; Madhi SA; Page N; McNeal M; Dally L; Cho I; Power M; Flores J; Cryz S
Lancet Infect Dis; 2020 Jul; 20(7):851-863. PubMed ID: 32251641
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of fully liquid and lyophilized formulations of an investigational trivalent group B streptococcus vaccine in healthy non-pregnant women: Results from a randomized comparative phase II trial.
Beran J; Leroux-Roels G; Van Damme P; de Hoon J; Vandermeulen C; Al-Ibrahim M; Johnson C; Peterson J; Baker S; Seidl C; Dreisbach A; Karsten A; Corsaro B; Henry O; Lattanzi M; Bebia Z
Vaccine; 2020 Apr; 38(16):3227-3234. PubMed ID: 32169390
[TBL] [Abstract][Full Text] [Related]
7. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial.
Heyderman RS; Madhi SA; French N; Cutland C; Ngwira B; Kayambo D; Mboizi R; Koen A; Jose L; Olugbosi M; Wittke F; Slobod K; Dull PM
Lancet Infect Dis; 2016 May; 16(5):546-555. PubMed ID: 26869376
[TBL] [Abstract][Full Text] [Related]
8. Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies.
Bézay N; Wagner L; Kadlecek V; Obersriebnig M; Wressnigg N; Hochreiter R; Schneider M; Dubischar K; Derhaschnig U; Klingler A; Larcher-Senn J; Eder-Lingelbach S; Bender W
Lancet Infect Dis; 2024 May; ():. PubMed ID: 38830375
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial.
Pollard AJ; Launay O; Lelievre JD; Lacabaratz C; Grande S; Goldstein N; Robinson C; Gaddah A; Bockstal V; Wiedemann A; Leyssen M; Luhn K; Richert L; Bétard C; Gibani MM; Clutterbuck EA; Snape MD; Levy Y; Douoguih M; Thiebaut R;
Lancet Infect Dis; 2021 Apr; 21(4):493-506. PubMed ID: 33217361
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in pregnant women and their infants: Results from a randomized placebo-controlled phase II trial.
Swamy GK; Metz TD; Edwards KM; Soper DE; Beigi RH; Campbell JD; Grassano L; Buffi G; Dreisbach A; Margarit I; Karsten A; Henry O; Lattanzi M; Bebia Z
Vaccine; 2020 Oct; 38(44):6930-6940. PubMed ID: 32883555
[TBL] [Abstract][Full Text] [Related]
12. A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization.
Buurman ET; Timofeyeva Y; Gu J; Kim JH; Kodali S; Liu Y; Mininni T; Moghazeh S; Pavliakova D; Singer C; Singh S; Handke LD; Lotvin J; Prasad AK; Scully IL; Donald RGK; Jansen KU; Anderson AS
J Infect Dis; 2019 Jun; 220(1):105-115. PubMed ID: 30778554
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chappell KJ; Mordant FL; Li Z; Wijesundara DK; Ellenberg P; Lackenby JA; Cheung STM; Modhiran N; Avumegah MS; Henderson CL; Hoger K; Griffin P; Bennet J; Hensen L; Zhang W; Nguyen THO; Marrero-Hernandez S; Selva KJ; Chung AW; Tran MH; Tapley P; Barnes J; Reading PC; Nicholson S; Corby S; Holgate T; Wines BD; Hogarth PM; Kedzierska K; Purcell DFJ; Ranasinghe C; Subbarao K; Watterson D; Young PR; Munro TP
Lancet Infect Dis; 2021 Oct; 21(10):1383-1394. PubMed ID: 33887208
[TBL] [Abstract][Full Text] [Related]
14. Association between anti-capsular IgG levels at birth and risk of invasive group B streptococcus disease in Finnish newborns: a retrospective case-control study.
Saukkoriipi A; Silmon de Monerri NC; Toropainen M; Lindholm L; Veijola R; Toppari J; Knip M; Radley D; Gomme E; Jongihlati B; Anderson AS; Palmu AA; Simon R
Lancet Microbe; 2024 Jul; 5(7):689-696. PubMed ID: 38679040
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
[TBL] [Abstract][Full Text] [Related]
16. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.
Toback S; Galiza E; Cosgrove C; Galloway J; Goodman AL; Swift PA; Rajaram S; Graves-Jones A; Edelman J; Burns F; Minassian AM; Cho I; Kumar L; Plested JS; Rivers EJ; Robertson A; Dubovsky F; Glenn G; Heath PT;
Lancet Respir Med; 2022 Feb; 10(2):167-179. PubMed ID: 34800364
[TBL] [Abstract][Full Text] [Related]
17. A randomized, observer-blind Phase Ib study to identify formulations and vaccine schedules of a trivalent Group B Streptococcus vaccine for use in non-pregnant and pregnant women.
Leroux-Roels G; Maes C; Willekens J; De Boever F; de Rooij R; Martell L; Bedell L; Wittke F; Slobod K; Dull P
Vaccine; 2016 Apr; 34(15):1786-91. PubMed ID: 26928074
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study.
Sridhar S; Joaquin A; Bonaparte MI; Bueso A; Chabanon AL; Chen A; Chicz RM; Diemert D; Essink BJ; Fu B; Grunenberg NA; Janosczyk H; Keefer MC; Rivera M DM; Meng Y; Michael NL; Munsiff SS; Ogbuagu O; Raabe VN; Severance R; Rivas E; Romanyak N; Rouphael NG; Schuerman L; Sher LD; Walsh SR; White J; von Barbier D; de Bruyn G; Canter R; Grillet MH; Keshtkar-Jahromi M; Koutsoukos M; Lopez D; Masotti R; Mendoza S; Moreau C; Ceregido MA; Ramirez S; Said A; Tavares-Da-Silva F; Shi J; Tong T; Treanor J; Diazgranados CA; Savarino S
Lancet Infect Dis; 2022 May; 22(5):636-648. PubMed ID: 35090638
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of the Vi-DT typhoid conjugate vaccine in healthy volunteers in Nepal: an observer-blind, active-controlled, randomised, non-inferiority, phase 3 trial.
Kumar Rai G; Saluja T; Chaudhary S; Tamrakar D; Kanodia P; Giri BR; Shrestha R; Uranw S; Kim DR; Yang JS; Park IY; Kyung SE; Vemula S; Reddy E J; Kim B; Gupta BP; Jo SK; Ryu JH; Park HK; Shin JH; Lee Y; Kim H; Kim JH; Mojares ZR; Wartel TA; Sahastrabuddhe S
Lancet Infect Dis; 2022 Apr; 22(4):529-540. PubMed ID: 34942090
[TBL] [Abstract][Full Text] [Related]
20. The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials.
Essink B; Chu L; Seger W; Barranco E; Le Cam N; Bennett H; Faughnan V; Pajon R; Paila YD; Bollman B; Wang S; Dooley J; Kalidindi S; Leav B
Lancet Infect Dis; 2023 May; 23(5):621-633. PubMed ID: 36682364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
